Genomic predictors of response to doxorubicin versus docetaxel in breast cancer
Ontology highlight
ABSTRACT: Low topo2a expression and ER-negative status were predictors of response to doxorubicin, while small tumor size and ER-negative status predicted response to docetaxel. Docetaxel was superior to doxorubicin in triple-negative/basal-like tumors, while no significant differences between these drugs were seen in the remaining intrinsic subtypes Keywords: reference x sample reference x sample
ORGANISM(S): Homo sapiens
SUBMITTER: Charles Perou
PROVIDER: E-GEOD-21997 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA